{"result": "(\"entity\"<|>CYSTIC FIBROSIS FOUNDATION<|>ORGANIZATION<|>The Cystic Fibrosis Foundation is an organization that provides guidelines and recommendations for the management of cystic fibrosis, including dietary and medical interventions.)\n##\n(\"entity\"<|>WHO<|>ORGANIZATION<|>The World Health Organization (WHO) provides formulas for calculating resting energy expenditure in various age groups.)\n##\n(\"entity\"<|>FIBROSIS QUÍSTICA<|>EVENT<|>Fibrosis quística is a genetic disorder that affects the lungs and digestive system, requiring specific dietary and medical management.)\n##\n(\"entity\"<|>OLIVEIRA G<|>PERSON<|>Oliveira G is a researcher who modified dietary recommendations for cystic fibrosis patients.)\n##\n(\"entity\"<|>TURK D<|>PERSON<|>Turk D is a researcher who provided modifications for sodium supplementation in cystic fibrosis patients.)\n##\n(\"entity\"<|>DHA<|>ORGANIZATION<|>DHA (Docosahexaenoic acid) is an essential fatty acid proposed for dietary supplementation in cystic fibrosis to modulate inflammatory responses.)\n##\n(\"entity\"<|>EPA<|>ORGANIZATION<|>EPA (Eicosapentaenoic acid) is another essential fatty acid that has been tested in combination with DHA for cystic fibrosis management.)\n##\n(\"entity\"<|>INSUFICIENCIA PANCREÁTICA EXOCRINA<|>EVENT<|>Exocrine pancreatic insufficiency (IPE) is a condition that affects nutrient absorption in cystic fibrosis patients.)\n##\n(\"entity\"<|>ENZIMAS PANCREÁTICAS<|>ORGANIZATION<|>Pancreatic enzymes are supplements used by cystic fibrosis patients to aid in the digestion of fats and improve nutrient absorption.)\n##\n(\"relationship\"<|>CYSTIC FIBROSIS FOUNDATION<|>WHO<|>The Cystic Fibrosis Foundation utilizes guidelines from the WHO for calculating energy expenditure in cystic fibrosis patients<|>7)\n##\n(\"relationship\"<|>CYSTIC FIBROSIS FOUNDATION<|>FIBROSIS QUÍSTICA<|>The Cystic Fibrosis Foundation provides recommendations for managing cystic fibrosis<|>8)\n##\n(\"relationship\"<|>OLIVEIRA G<|>CYSTIC FIBROSIS FOUNDATION<|>Oliveira G modified dietary recommendations for cystic fibrosis patients as per the guidelines of the Cystic Fibrosis Foundation<|>6)\n##\n(\"relationship\"<|>TURK D<|>CYSTIC FIBROSIS FOUNDATION<|>Turk D provided modifications for sodium supplementation in cystic fibrosis patients, which are included in the Cystic Fibrosis Foundation's guidelines<|>6)\n##\n(\"relationship\"<|>DHA<|>FIBROSIS QUÍSTICA<|>DHA is proposed for dietary supplementation to improve clinical outcomes in cystic fibrosis patients<|>5)\n##\n(\"relationship\"<|>EPA<|>FIBROSIS QUÍSTICA<|>EPA is tested in combination with DHA for dietary management in cystic fibrosis<|>5)\n##\n(\"relationship\"<|>INSUFICIENCIA PANCREÁTICA EXOCRINA<|>ENZIMAS PANCREÁTICAS<|>Patients with exocrine pancreatic insufficiency require pancreatic enzymes for proper digestion<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: |---|\n| Sexo | V | M | V | M | V | M | V | M | V | M |\n| Kcal/Kg/día | 31 | 30 | 38 | 35 | 41 | 37 | 50 | 44 | 58 | 51 |\n\n## Método 3: Fórmula de la Cystic Fibrosis Foundation* (adultos y niños)\n\nGET = GER (Gasto energético en reposo) x (Coeficiente de actividad + Coeficiente de enfermedad) x Coeficiente de absorción de grasa\n\nGasto energético en reposo (fórmulas de la OMS):\n\n| Edad | Mujeres | Varones |\n|---|---|---|\n| 0-3 | 61 x peso - 51 | 60,9 x peso - 54 |\n| 3-10 | 22,5 x peso + 499 | 22,7 x peso + 495 |\n| 10-18 | 12,2 x peso + 746 | 17,5 x peso + 651 |\n| 18-30 | 14,7 x peso + 496 | 15,3 x peso + 679 |\n| 30-60 | 8,7 x peso + 829 | 11,6 x peso + 879 |\n\n- Nivel de actividad: En cama = 1,3. Sedentario = 1,5. Activo = 1,7.\n\n- Coeficiente de enfermedad: Función pulmonar normal (FEV 1 ≥ 80%) = 0. Disfunción moderada (FEV 1 40-80%) = 0,2. Disfunción severa (FEV 1 ≤ 40%) = 0,3-0,5.\n\n- Coeficiente de absorción de grasa: En pacientes sin IPE o con absorción normal (es decir > 93%) no aplicar coeficiente de corrección. En pacientes con porcentaje de absorción menor del 93% aplicar el siguiente coeficiente: 0,93/% de grasa absorbida (expresado en decimal). Por ejemplo: absorción del 80% poner 0,80; es decir: 0,93/0,80 = 1,1625 (en caso de no disponer del dato aplicar 0,85).\n\nGET: gasto energético total; V: varones; IPE: insuficiencia pancreática exocrina; M: mujeres.\n* Modificado de Olveira G.\n---\n568      BLOQUE: PATOLOGÍAS ESPECÍFICAS\n\nTabla 8. Suplementación con sal en la fibrosis quística.\n\n| Edad | Suplementación de sodio | Comentarios |\n|------|-------------------------|-------------|\n| 0-6 meses | 1-2 mmol/kg/día | Si riesgo de déficit de sodio, dar sal en pequeñas cantidades repartidas a lo largo del día en agua o zumos |\n| Niños con requerimientos especiales | Hasta 4 mmol/kg/día | Aumentar aporte en niños que viven en ambientes muy calurosos o si se incrementan las pérdidas debido a vómitos, fiebre, ostomías, etc. |\n| Niños mayores y adultos | Alimentos salados o sal en cápsulas o viales | Suplementar en situaciones de estrés en las que se prevé hipersudoración (fiebre, ejercicio, ambiente muy caluroso, etc.) |\n\nPara convertir mmol a mg de sodio, cloro o sal (cloruro sódico) multiplicar por 23, 35 o 58, respectivamente.\nModificada de: Turk D et al.52.\n\n5.1.2. Ácidos grasos esenciales\n\nSe ha propuesto la suplementación dietética con diversos ácidos grasos, especialmente DHA (aunque también se han probado combinaciones con eicosapentaenoico (EPA) y/o gammalinolénico) como una forma de modular la respuesta proinflamatoria en la FQ. Los estudios en humanos han demostrado que es posible mejorar el perfil de ácidos grasos en la FQ, disminuir parámetros inflamatorios y, en algunos casos, mejorar parámetros clínicos relacionados con el pronóstico de los pacientes como las reagudizaciones65, 66, 75. No obstante, la revisión Cochrane recoge que son necesarios más estudios para poder realizar recomendaciones clínicas basadas en la evidencia75.\n\n5.1.3. Enzimas pancreáticas\n\nLos pacientes con IPE, toleran perfectamente una dieta normal o alta en grasa si son tratados con enzimas pancreáticas a las dosis adecuadas. Así, en la mayoría, es posible alcanzar unos porcentajes de absorción de grasa entre el 85 y el 95% de la ingesta con las formulaciones del mercado. Las enzimas están recubiertas por una cubierta entérica que se disuelve en medio básico. Por tanto, no se pueden mezclar con productos alimenticios con pH básico (lácteos o antiácidos) y tampoco masticar o machacar. No existe un consenso claro sobre cuál es el mejor momento de administración. En general, se recomienda tomar antes de las comidas y\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}